Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL854618 | 0.95 | TSHR (0.33) | TSHRMAPK1MEN1KMT2ATHRB | |
| SCHEMBL2482893 | 0.92 | TSHR (0.32) | TSHRMAPK1 | |
| SCHEMBL6285483 | 0.89 | TSHR (0.36) | TSHRMAPK1MEN1KMT2ATHRB | |
| SCHEMBL11281488 | 0.88 | TSHR (0.30) | TSHR | |
| SCHEMBL8966981 | 0.86 | TSHR (0.38) | TSHRALDH1A1MEN1KMT2ATHRB | |
| SCHEMBL21443951 | 0.84 | GAA (0.36) | TSHRMAPK1MEN1KMT2ATHRB | |
| SCHEMBL27754281 | 0.83 | TSHR (0.32) | TSHRMAPK1ALDH1A1TP53CYP3A4 | |
| SCHEMBL15463146 | 0.83 | TSHR (0.50) | TSHRMAPK1ALDH1A1TP53CYP3A4 | |
| SCHEMBL21451457 | 0.82 | GAA (0.39) | TSHRMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL10952787 | 0.81 | CYP4F2 (0.33) | MEN1KMT2ATHRBHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025035209-A1 | LABEL-FREE MULTIMERIC APTAMER BIOSENSOR SYSTEM FOR REAL-TIME MONITORING OF TARGET ANALYTES IN A ONE-POT CONFIGURATION | MCMASTER UNIVERSITY (CA) | 2025-02-20 | — | — | WO | disclosed |
| US-20160017323-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-9181550-B2 | Compositions and methods for modulating apolipoprotein (a) expression | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9145558-B2 | Compositions and methods for modulating HBV expression | ISIS PHARMACEUTICALS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145558-B2 | Compositions and methods for modulating HBV expression | ISIS PHARMACEUTICALS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9127276-B2 | Conjugated antisense compounds and their use | ISIS PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150176007-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150126720-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20140343123-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150176007-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | HAVCR2, HCCS, HDGF | TSHR 3930/4885MAPK1 4339/4885ALDH1A1 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.